Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

Summary

The degenerative disc disease market is projected to grow at approximately 19% CAGR through 2036, driven by emerging regenerative therapies including cell replacement, NF-kappa B inhibitors, and cartilage regeneration approaches, marking a shift from traditional symptom-focused treatments to disease-modifying options.